SEOUL (Reuters) – A South Korean advisory board has recommended caution over the use of AstraZeneca’s COVID-19 vaccine for people over the age of 65 due to the lack of sufficient data, the Ministry of Food and Drug Safety said on Friday.
When approved, it will be the first COVID-19 vaccine to be approved for emergency use in Asia’s fourth-largest economy, which has been trying to contain the latest wave of infections.
South Korea signed a deal in December with AstraZeneca to secure 20 million doses of its vaccine, with the first shipment expected as early as this month.
(Reporting by Sangmi Cha; Editing by Jacqueline Wong)
